Neuromuscular

As part of NeurologyLive®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year.

The Distinguished Professor of Neuromuscular Disease at University of North Carolina School of Medicine offered his insight into the newly approved Argenx agent, marketed as Vyvgart. [WATCH TIME: 3 minutes]

We’ve compiled the top stories from 2021 across the breadth of the neuromuscular field, from clinical developments to conversations in management and beyond.

As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Neurology News Network for the week ending December 25, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

Two patients with late infantile GM1 gangliosidosis in Cohort 1 received a low dose of the treatment, reporting no serious adverse events. Passage Bio noted it plans to move forward with 2 additional cohorts.

The FDA has placed the investigational new drug application for the treatment on clinical hold.

The treatment was well-tolerated in children with AS, positively affecting constipation, a common symptom of the condition.

Here's what is coming soon to NeurologyLive®.

The phase 4 study will enroll 300 patients with amyotrophic lateral sclerosis who have started treatment with edaravone (Radicava; Mitsubishi Tanabe Pharma America).

Argenx’s antibody fragment to target the neonatal Fc receptor is the first in its class, with its approval backed by data from the phase 3 ADAPT trial.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.

The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Statistical significance was observed for both the MycarinG study’s primary and secondary end points in a population of 200 patients with myasthenia gravis treated with the UCB agent.

Kent Pryor, PhD, the CEO of ZZ Biotech, provided insight into a phase 2 trial that will evaluate the safety and efficacy of the investigational treatment in 16 patients with amyotrophic lateral sclerosis.